There are currently 582 clinical trials in Omaha, Nebraska looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Nebraska Medical Center, Creighton University Medical Center, Nebraska Methodist Hospital and Alegent Health Bergan Mercy Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
NCT04329728
Recruiting
This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.
Gender:
ALL
Ages:
Between 12 years and 95 years
Trial Updated:
02/13/2024
Locations: Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha, Nebraska
Conditions: Lymphoid Malignancies
Register for Updates
Hyperbaric Oxygen Brain Injury Treatment Trial
NCT02407028
Recruiting
The purpose of this innovative adaptive phase II trial design is to determine the optimal combination of hyperbaric oxygen treatment parameters that is most likely to demonstrate improvement in the outcome of severe TBI patients in a subsequent phase III trial.
Gender:
ALL
Ages:
Between 16 years and 65 years
Trial Updated:
02/06/2024
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Traumatic Brain Injury
Register for Updates
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
NCT04137900
Recruiting
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Advanced Unresectable Solid Tumor, Metastatic Solid Tumor
Register for Updates
BlueWind RENOVA iStim™ System for the Treatment of OAB
NCT03596671
Recruiting
The OASIS study is prospective, interventional, multi-center study to evaluate the safety and efficacy of the BlueWind RENOVA iStim™ implantable tibial neuromodulation System for the treatment of patients diagnosed with overactive bladder.
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
12/29/2023
Locations: Adult Pediatric Urology & Urogynecology, Omaha, Nebraska
Conditions: Treatment of Patients Suffering From Overactive Bladder (OAB)
Register for Updates
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
NCT04197687
Recruiting
This phase II trial studies how well TPIV100 and sargramostim work in treating patients with HER2 positive, stage II-III breast cancer that has residual disease after chemotherapy prior to surgery. It also studies why some HER2 positive breast cancer patients respond better to chemotherapy in combination with trastuzumab and pertuzumab. TPIV100 is a type of vaccine made from HER2 peptide that may help the body build an effective immune response to kill tumor cells that express HER2. Sargramostim... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/15/2023
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Register for Updates
Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants
NCT05865041
Recruiting
The main purpose of this study is to measure the efficacy of farudodstat compared to placebo at Week 12 from the treatment start, in adult participants with Alopecia Areata (AA) with 30% or greater scalp hair loss.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2023
Locations: 1 Site, Omaha, Nebraska
Conditions: Alopecia Areata
Register for Updates
Polyomic Biomarker Verification in Adult Chronic Graft-Versus-Host Disease (ABLE3.0/CTTC2201)
NCT05692713
Recruiting
Chronic graft-versus-host disease (cGvHD) is one of the most serious complications following BMT (Bone Marrow Transplantation). cGvHD occurs when donor immune cells "attack" the tissues and organs of the person receiving the BMT. cGvHD can be difficult to treat once it is established leading to poor quality of life for recipients of a BMT. The goal of this study is to determine if, by using biomarkers, the investigators can predict which patients are at the highest risk of developing cGvHD after... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2023
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Chronic Graft-versus-Host-Disease, Allogeneic Hematopoietic Stem Cell Transplantation, Leukemia, Blood Cancer, Non-Malignant Hematologic and Lymphocytic Disorder
Register for Updates
The Pediatric Anesthesia Quality Improvement Project
NCT00674388
Recruiting
The Study is designed to collect information about adverse events that occur in children undergoing anesthesia in participating hospitals. Demographic information will be collected on all anesthetics. An analysis of each adverse event will be performed and entered into the database. From this information we will devise strategies to prevent these adverse events.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
11/20/2023
Locations: Children's Hospital and Medical Center, Omaha, Nebraska
Conditions: Surgery, Anesthesia, Children
Register for Updates
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
NCT05283330
Recruiting
A Phase 1 SAD/MAD dose escalation and expansion study to determine the safety and effectiveness of ²¹²Pb-DOTAM-GRPR1 in subjects with various GRPR-expressing Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: XCancer Omaha / Urology Cancer Center, Omaha, Nebraska
Conditions: Cervical Cancer, Prostate Cancer Metastatic, Breast Cancer, Colon Cancer, NSCLC, Cutaneous Melanoma
Register for Updates
Therapeutic Use of Contrast Ultrasound in Acute Coronary Artery Disease
NCT04732091
Recruiting
Preclinical studies have demonstrated that high mechanical index (MI) impulses from a diagnostic ultrasound (DUS) transducer during an intravenous microbubble infusion (sonothrombolysis) can restore epicardial and microvascular flow in acute ST-segment elevation myocardial infarction (STEMI). The investigators propose to demonstrate the clinical effectiveness of sonothrombolysis in multiple centers and in a wide scenario of acute coronary syndromes.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
10/06/2023
Locations: Department of Internal Medicine, Division of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Acute Myocardial Infarction, Unstable Angina
Register for Updates
CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology
NCT02577302
Recruiting
This is a prospective, randomized, controlled, multi-center, study in which 150 evaluable subjects will be randomized 1:1 to receive either a Protect CAN-Stim or SNS InterStim® system. Subjects from both groups will immediately start with therapy. The primary endpoint is a ≥ 50% reduction in number of incontinence episodes associated with urgency at the 3-month visit, with additional measurements assessed at 14 days, 1, 6, 9 and 12-months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2023
Locations: Adult & Pediatric Urology, P.C., Omaha, Nebraska
Conditions: Urinary Incontinence, Urge
Register for Updates
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
NCT03547115
Recruiting
This is a Phase 1, open-label, dose escalation study to determine the safety and preliminary efficacy of voruciclib monotherapy in subjects with relapsed/refractory B cell malignancies or AML after failure of standard therapies or voruciclib in combination with venetoclax in subjects with relapsed or refractory AML
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/03/2023
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
Register for Updates